Biotech entity
pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Therapeutic Goods Administration (TGA) is most often covered alongside Bilal Cassim, which appears in 1 of these 3 stories. They are less corroborated than the beat average, carrying 2.3 original sources each against 3.4 for the same window.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Therapeutic Goods Administration (TGA) is most often covered alongside Bilal Cassim, which appears in 1 of these 3 stories. They are less corroborated than the beat average, carrying 2.3 original sources each against 3.4 for the same window. Across a 22-day span, the pace is roughly 1 story per week. At 6.3, the average consequence score sits above the same-window beat average of 6.1. Therapeutic Goods Administration (TGA) appears in 3 tracked Biotech stories published from February 27, 2026 through March 20, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 282 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Therapeutic Goods Administration (TGA). Shared-story counts are live from our verified record — not editorial picks.
Bilal Cassim’s public testimony regarding the efficacy of medicinal cannabis for PTSD and sleep disorders highlights a growing trend of patient-led advocacy in Australia. This case underscores the shifting clinical landscape as researchers and regulators grapple with the integration of cannabinoid therapies into standard psychiatric care.
A comprehensive study published in The Lancet concludes that medicinal cannabis is largely ineffective for treating anxiety, depression, and PTSD. These findings challenge the rapidly growing global market for cannabinoid-based mental health treatments and highlight a significant gap between patient perception and clinical evidence.
The Australian government is significantly reducing subsidies for high-cost spinal cord stimulators following reports of severe patient injuries and a lack of clinical efficacy. This regulatory shift targets a multi-million dollar sector of the medical device market, forcing manufacturers to justify the high price tags of chronic pain technologies.
Therapeutic Goods Administration (TGA) is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
